Immutep S.A. is a biopharmaceutical company developing immunotherapeutics in oncology. Our products include a T cell immunostimulatory factor (APC activator) for cancer chemo-immunotherapy and a therapeutic antibody for immune response modulation in cancer. The Company's technologies are based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response.

Interview Frederic Triebel, founder, Immutep, with PharmaTelevision.

Get the Flash Player to see this video.

© 2002 Immutep, S.A.